Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 472 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 472 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.29, for a total value of $11,936.88. Following the completion of the sale, the senior vice president now directly owns 172,743 shares in the company, valued at approximately $4,368,670.47. The trade was a 0.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Artivion Price Performance

Shares of NYSE AORT opened at $24.78 on Friday. The firm has a 50-day simple moving average of $29.23 and a 200-day simple moving average of $27.80. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -1,239.05 and a beta of 1.79. Artivion, Inc. has a 52 week low of $19.11 and a 52 week high of $32.33.

Artivion (NYSE:AORT) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its holdings in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after buying an additional 786 shares during the period. Quarry LP increased its stake in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the period. R Squared Ltd acquired a new stake in shares of Artivion during the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion in the fourth quarter valued at approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion in the fourth quarter valued at approximately $64,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on AORT shares. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer upped their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, Needham & Company LLC lowered their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion presently has an average rating of “Buy” and an average target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.